Survodutide — Dual GLP-1/Glucagon Receptor Agonist for NASH & Obesity Research
Survodutide (BI 456906), developed by Boehringer Ingelheim, is a dual GLP-1 and glucagon receptor co-agonist demonstrating exceptional potential in both obesity and NASH research. While sharing a dual-agonist mechanism with Mazdutide, Survodutide’s unique molecular design and glucagon potency profile has generated compelling data in metabolic liver disease — an underserved area of research.
Reconstitution: Reconstitute with Bacteriostatic Water (BAC Water) for multi-use stability, or Sterile Water for single-use protocols. Store lyophilized vials at 2–8°C.
Key Research Areas
⚡ Obesity & Weight Loss
Phase 2 data shows dose-dependent weight reduction of up to 19% over 46 weeks, placing Survodutide among the most effective compounds in the dual-agonist class. Phase 3 LIGHT UP trial is ongoing for obesity.
🧬 NASH Research — Leading Compound
Phase 2 LIGHT ON trial demonstrated 69% NASH resolution rate at highest dose — significantly exceeding placebo. Survodutide’s glucagon receptor activity drives hepatic lipid oxidation and reduces steatosis, fibrosis, and liver enzyme markers in NASH models.
🔥 Metabolic Syndrome
Research models show improvements in multiple metabolic syndrome components simultaneously: visceral adiposity, insulin resistance, dyslipidaemia, and hypertension — relevant across cardiovascular-metabolic research.
❤️ Cardiovascular Research
Early data suggests beneficial effects on cardiovascular risk markers consistent with GLP-1 class compounds, with ongoing research in the LIGHT WEIGHT cardiovascular outcomes trial.
Why Choose EhBuddy?
- ✅ Verified Purity — Third-party tested for identity and potency
- ✅ Fast Canadian Shipping — Discreet packaging, shipped from Canada
- ✅ Research-Grade Quality — Strict manufacturing quality standards
FOR RESEARCH USE ONLY (RUO). Not approved for human or veterinary use. Intended for in vitro and laboratory research only. EhBuddy Peptides assumes no liability for misuse.














Reviews
There are no reviews yet.